Pyrazino<2,3-d>pyridazin | 254-95-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: Pyrazino<2,3-d>pyridazin
• 英文别名: 1,4,6,7-Tetraazanaphthalin；pyrazino[2,3-d]pyridazine；Pyrazino[2,3-d]pyridazine
• CAS: 254-95-5
• 化学式: C₆H₄N₄
• 分子量: 132.125
• InChiKey: XFEVEGNEHPLFGK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  51.6
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• [EN] SMALL MOLECULE DCN1 INHIBITORS AND THERAPEUTIC METHODS USING THE SAME<br/>[FR] INHIBITEURS DE DCN1 À PETITES MOLÉCULES ET PROCÉDÉS THÉRAPEUTIQUES LES UTILISANT
  申请人：UNIV MICHIGAN REGENTS

  公开号：WO2018183411A1

  公开（公告）日：2018-10-04

  Compounds of formula (I) as inhibitors of DCNl and compositions containing the same are disclosed. Methods of using the DCNl inhibitors in the treatment of diseases and conditions wherein inhibition of DCNl provides a benefit, like oxidative stress-related diseases and conditions, neurodegenerative diseases and conditions, metabolic disorders, and muscular nerve degeneration, also are disclosed.

  公式（I）的化合物被披露为DCNl的抑制剂，以及含有这些化合物的组合物。还披露了在治疗疾病和病况中使用DCNl抑制剂的方法，其中DCNl的抑制提供益处，如氧化应激相关的疾病和病况、神经退行性疾病和病况、代谢紊乱以及肌肉神经退化。
• Covalent Small Molecule DCN1 Inhibitors and Therapeutic Methods Using the Same
  申请人：THE REGENTS OF THE UNIVERSITY OF MICHIGAN

  公开号：US20180289677A1

  公开（公告）日：2018-10-11

  Small molecule covalent inhibitors of DCN1 and compositions containing the same are disclosed. Methods of using the DCN1 covalent inhibitors in the treatment of diseases and conditions wherein inhibition of DCN1 provides a benefit, like oxidative stress-related diseases and conditions, neurodegenerative diseases and conditions, metabolic disorders, and muscular nerve degeneration, also are disclosed.

  揭示了DCN1的小分子共价抑制剂和含有这些抑制剂的组合物。还揭示了在治疗疾病和状况中使用DCN1共价抑制剂的方法，其中DCN1的抑制提供益处，如氧化应激相关的疾病和状况、神经退行性疾病和状况、代谢紊乱以及肌肉神经退化。
• Ion conducting polymers
  申请人：——

  公开号：US20040171781A1

  公开（公告）日：2004-09-02

  A compound having the general formula (I): − O 3 S—R 1 —V 1 —R 2 —V 2 wherein R 1 is a hydrocarbon radical comprising C 1 to C 10 main chain carbon atoms, wherein hydrogen atoms bonded to the main chain carbon atoms are optionally substituted; R 2 is a hydrocarbon radical comprising 6 to 20 main chain carbon atoms, wherein hydrogen atoms bonded to the main chain carbon atoms are optionally substituted; V 1 is a saturated or unsaturated, monocyclic or bicyclic ring system comprising 5 to 9 ring atoms, wherein at least 2 ring atoms are nitrogen atoms forming the same cyclic moiety; and V 2 is a moiety comprising a carboxyl group and an unsaturated carbon-carbon bond.

  一个具有通式（I）的化合物：−O3S—R1—V1—R2—V2其中R1是一个含有C1到C10主链碳原子的烃基，主链碳原子上的氢原子可以选择性地被取代；R2是一个含有6到20个主链碳原子的烃基，主链碳原子上的氢原子可以选择性地被取代；V1是一个饱和或不饱和的、单环或双环的环系统，含有5到9个环原子，其中至少有2个环原子是氮原子组成的同一个环基；V2是一个含有羧基和不饱和碳-碳键的基团。
• CINNAMOYL COMPOUND AND USE THEREOF
  申请人：Sumitomo Chemical Company, Limited

  公开号：EP1857455A1

  公开（公告）日：2007-11-21

  Disclosed is an extracellular matrix genetranscription inhibitor composition or the like characterized by containing a cinnamoyl compound represented by the formula(I) below: and an inert carrier.

  揭示了一种包含下面式(I)所代表的肉桂酰化合物和惰性载体的细胞外基质基因转录抑制剂组合物或类似物。
• [EN] MONOBACTAMS AND METHODS OF THEIR SYNTHESIS AND USE<br/>[FR] MONOBACTAMES ET PROCÉDÉS DE SYNTHÈSE ET D'UTILISATION DE CES DERNIERS
  申请人：HARVARD COLLEGE

  公开号：WO2015103583A1

  公开（公告）日：2015-07-09

  Described herein are monobactam antibiotics of Formula (I), (Ι'), (II), and (II'), along with methods and intermediates for preparing these compounds. Pharmaceutical compositions and methods of treating infectious diseases using the monobactams are also provided.

  本文描述了单环内酰胺抗生素的化学式(I)、(Ι')、(II)和(II')，以及制备这些化合物的方法和中间体。还提供了使用单环内酰胺治疗传染病的药物组合物和方法。